ArticleBMC microbiology2025
Expression of bap gene in multidrug-resistant and biofilm-producing Acinetobacter baumannii clinical isolates.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Review
- Genetic profiling of biofilm-associated genes (bap, ompA, csuE, and blaPER-1) in Acinetobacter baumannii clinical isolates.Archives of microbiology · 2026Article
- Article
- Prevalence and associations of antibiotic resistance and biofilm formation with molecular determinants in clinical Acinetobacter baumannii isolates.Scientific reports · 2026Article
- Repurposing Fingolimod as an Antibacterial and Antibiofilm Agent against Carbapenem-ResistantACS omega · 2026Article
- In vitro evaluation of anti-inflammatory drugs Ibuprofen and Dexamethasone against Acinetobacter baumannii.BMC microbiology · 2026Article
- New Insights intoPathogens (Basel, Switzerland) · 2026Review
- Virulence arsenal of Acinetobacter baumannii: mechanisms driving persistence and resistance.Archives of microbiology · 2026Review
- Scorpion Venom-Derived Peptides: A New Weapon Against Carbapenem-ResistantMicroorganisms · 2025Article
- Preliminary Assessment ofGenes · 2025Article
- Natural product-based inhibitors of quorum sensing: A novel approach to combat antibiotic resistance.Biochemistry and biophysics reports · 2025Review
- When the Last Line Fails: Characterization of Colistin-ResistantPathogens (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionAcinetobacter baumannii is a significant biofilm-producer and antibiotic-resistant pathogen associated with various infections caused in humans. This study aimed to investigate the expression level of the bap gene in multidrug-resistant and biofilm-producer clinical isolates of A. baumannii. MATERIALS AND
methodsOne Hundred A. baumannii clinical isolates were collected from hospitalized patients and identified by phenotypic and genotypic tests. The antibiotic resistance pattern of the isolates was determined by the disk agar diffusion method. The ability of biofilm production was investigated using the microtiter plate test. This study employed the Real-time PCR method to evaluate the expression level of the bap gene.
resultsNinety nine percent A. baumannii isolates were MDR. However, the highest resistance rate was observed against ciprofloxacin (100%), while ceftazidime was the most effective drug. Also, 49%, 49%, and 2% of the isolates were strong, moderate, and weak biofilm-producing, respectively. However, we detected no strain without the ability to produce biofilm. Most strong and moderate biofilm-former isolates were non-susceptible to all tested antibiotics. An increased expression level of the bap gene was detected in 99% of the isolates. The results of the present study suggest a correlation between the bap gene expression level and the development of multidrug resistance and biofilm formation in A. baumannii isolates.
conclusionThis research emphasizes the importance of biofilm formation in the emergence of multidrug-resistant A. baumannii strains in healthcare settings, making them progressively difficult to control. The bap gene may be a considerable target for the development of novel anti-A. baumannii treatment option and eradication of the biofilm formation by this organism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.